MYRIAD GENETICS INC

Insider buy: Myriad Genetics’ chief commercial officer increases holdings to 573,363 shares, signaling confidence amid market volatility.

Myriad Genetics’ new commercial leader, Vishal Sikri, receives a 257,731 RSU grant—an insider confidence vote that may spur oncology growth and stabilize returns.

Insider sale at Myriad Genetics shows disciplined liquidity, not panic; learn why Rashmi Kumar’s 15k share sell signals confidence, not risk.

Insider buying of Myriad Genetics shares signals management confidence in its expanding equity plan and diagnostic pipeline, hinting at potential upside amid current volatility.

Insider Paul Bisaro buys 7,500 Myriad Genetics shares at $3.69 as the stock drops 26.3%—a cautious bet on the company’s diagnostic pipeline.

Insider selling at Myriad Genetics shows routine portfolio balancing, not a red flag, and highlights strong long‑term confidence amid market volatility.

Insightful look at Myriad Genetics insider sales: COO Mark Verratti’s April 2026 trade, its context, and what it signals for investors.

Insider buying surge at Myriad signals confidence amid volatility: 104,000+ shares purchased, potential upside, and strategic pipeline insights.